In the Claims

Claim 1 (Currently amended): A method of increasing the number of <u>hematopoietic</u> stem cells in a patient, comprising administering an effective amount of an RNA interference molecule targeting SH2-domain containing inositol 5-phosphatase (SHIP) to the patient, wherein the number of <u>hematopoietic</u> stem cells in the patient are thereby increased.

Claims 2-17 (Cancelled)

Claim 18 (Previously presented): The method of claim 1, further comprising harvesting the stem cells from the patient after said administering.

Claim 19 (Previously presented): The method of claim 18, wherein said harvesting comprises leukopheresis.

Claim 20 (Previously presented): The method of claim 18, further comprising administering the harvested stem cells to the patient.

Claim 21 (Cancelled)

Claim 22 (Previously presented): The method of claim 1, wherein the RNA interference molecule is administered intravenously.

Claim 23 (Cancelled)

Claim 24 (Previously presented): The method of claim 1, wherein said administering mobilizes the stem cells to the peripheral blood.

Claim 25 (Previously presented): The method of claim 1, wherein the patient has undergone myeloablation.

Claim 26 (New): A method of increasing the number of embryonic stem cells in a patient, comprising administering an effective amount of an RNA interference molecule targeting SH2-domain containing inositol 5-phosphatase (SHIP) to the patient, wherein the number of embryonic stem cells in the patient are thereby increased.

Claim 27 (New): The method of claim 26, further comprising harvesting the stem cells from the patient after said administering.

Claim 28 (New): The method of claim 27, wherein said harvesting comprises leukopheresis.

Claim 29 (New): The method of claim 27, further comprising administering the harvested stem cells to the patient.

Claim 30 (New): The method of claim 26, wherein the RNA interference molecule is administered intravenously.

Claim 31 (New): The method of claim 26, wherein said administering mobilizes the stem cells to the peripheral blood.

Claim 32 (New): The method of claim 26, wherein the patient has undergone myeloablation.

Claim 33 (New): The method of claim 1, wherein the RNA interference molecule is administered to the patient for 1 week or 2 weeks.

Claim 34 (New): The method of claim 26, wherein the RNA interference molecule is administered to the patient for 1 week or 2 weeks.